IMR Press / EJGO / Volume 41 / Issue 3 / DOI: 10.31083/j.ejgo.2020.03.5291
Open Access Original Research
Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older
Show Less
1 Department of Obstetrics and Gynecology, Anhui Provincial Hospital, Anhui Medical University,230001, Hefei, China
2 Department of Obstetrics and Gynecology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230001, Hefei, China
3 Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230001, Hefei, China
4 Organ Transplantation Center, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230001, Hefei, China
Eur. J. Gynaecol. Oncol. 2020 , 41(3), 415–421; https://doi.org/10.31083/j.ejgo.2020.03.5291
Submitted: 8 June 2019 | Accepted: 5 September 2019 | Published: 15 June 2020
Abstract

Objective: To describe the clinical features associated with the treatment and survival outcomes of older women with epithelial ovarian cancer. Materials and methods: Fifty-five women aged ≥ 65 years and diagnosed with epithelial ovarian cancer were enrolled. The clinical characteristics, treatment procedure and survival outcomes were presented and analyzed. Results: The mean age at the time of epithelial ovarian cancer diagnosis was 69.9 ± 3.9 years, with most women presenting with advanced stage disease (83.6%). Thirty-five patients (63.6%) received optimal cytoreduction, of whom 23 underwent surgery with a low surgical complexity score Forty-two percent of patients presented with postoperative complications, while five patients presented with three or more postoperative complications simultaneously. The large majority (87.3%) of patients received chemotherapy, and more than half (42%) relapsed. The three-year overall survival rate was 52.8%, while three-year progression-free survival was 33.3%. Advanced FIGO stage and residual lesions were the factors associated with reduced overall survival (p < 0.0001, p = 0.004), FIGO stage was also associated with progression-free survival (p = 0.001). Conclusions: Aggressive surgical debulking and chemotherapy are feasible for older epithelial ovarian cancer patients. Advanced FIGO stage and residual lesions are associated with reduced survival.

Keywords
Geriatric patients
Epithelial ovarian cancer
Cytoreduction
Chemotherapy
Survival
Figures
Figure 1.
Share
Back to top